PandaOmics

? The latest from PandaOmics! Introducing PandaOmics Box. Transform the #research landscape, empowering researchers to excel in target identification, biomarker discovery and indication prioritization. Hear from Insilico Medicine's CEO, Alex Zhavoronkov to learn more about this new #drugdiscovery toolkit. Visit our website today: https://lnkd.in/dsviKa7e

Thank you, Clarivate and thanks to my team for turning some dreams in biology, chemistry and even in clinical trials into reality. From the very inception of Insilico we committed to making our work as transparent as commercially possible. Most of our AI is commercially-available. Get your Pharma.AI suite from Petrina Kamya, Ph.D. today! https://lnkd.in/guC4TjN8

?? AI-driven drug shows promising Phase IIa results in treating fatal lung disease! ?? Insilico Medicine just announced breakthrough results from its Phase IIa clinical trial for ISM001-055, an AI-designed drug candidate for idiopathic pulmonary fibrosis (IPF). This novel treatment could transform options for IPF, a disease with very few effective therapies available today. Why This Matters IPF is a chronic, progressive lung disease that affects nearly 5 million people worldwide, with a median survival of only 3-4 years. Current treatments help slow disease progression but can't stop or reverse it. Insilico's ISM001-055 was developed using cutting-edge generative AI, targeting TNIK (Traf2- and NCK-interacting kinase), a key driver of lung fibrosis, to offer a potentially disease-modifying treatment. ?? Key Highlights: ???ISM001-055, discovered and designed using @Biology42 (PandaOmics) and Chemistry42 ???Three differing doses of ISM001-055 were assessed against placebo Each was "well-tolerated" ???Each group also had improved FVC, but researchers reported that it was dose dependent ???Patients with idiopathic pulmonary fibrosis had improved FVC between baseline and 12 weeks with receipt of ISM001-055, a small molecule targeting Traf2- and Nck-interacting kinase, vs. placebo ?? Trial details: Randomized, double-blind, placebo-controlled 71 IPF patients across 21 sites in China Treatment duration: 12 weeks Dosing groups: placebo, 30mg once daily (QD), 30mg twice daily (BID), or 60mg QD ?? The drug: ISM001-055 Novel small molecule inhibitor targeting TNIK (TRAF2 and NCK-interacting kinase) Designed to tackle multiple pro-fibrotic pathways driving IPF pathology ?? Rapid development timeline: 2019: TNIK identified as target using Biology AI 2020: ISM001-055 synthesized with Chemistry AI 2021: Preclinical candidate nomination 2021-2023: Phase 0 microdose and Phase 1 trials completed 2023-2024: Phase 2a trial conducted Insilico is now recruiting for a parallel Phase IIa trial in the United States to further validate the efficacy and safety of ISM001-055. If successful, this drug could shift the treatment paradigm for IPF. Alex Zhavoronkov #GenAI #AI #DrugDiscovery

This awesome video covers our recent announcement exceptionally well! Insilico Medicine PandaOmics Chemistry42

BREAKING: AI-driven drug shows promising Phase IIa results in treating fatal lung disease! Insilico Medicine just announced breakthrough results from its Phase IIa clinical trial for ISM001-055, an AI-designed drug candidate for idiopathic pulmonary fibrosis (IPF). This novel treatment could transform options for IPF, a disease with very few effective therapies available today. ?? Why This Matters IPF is a chronic, progressive lung disease that affects nearly 5 million people worldwide, with a median survival of only 3-4 years. Current treatments help slow disease progression but can’t stop or reverse it. Insilico’s ISM001-055 was developed using cutting-edge generative AI, targeting TNIK (Traf2- and NCK-interacting kinase), a key driver of lung fibrosis, to offer a potentially disease-modifying treatment. ?? Key Findings from Phase IIa ?? Trial Design: Double-blind, placebo-controlled study with 71 IPF patients across 21 sites in China. Patients were given one of three doses or a placebo over 12 weeks. ?? Lung Function Improvements: Patients on the highest dose (60 mg) showed a mean increase in forced vital capacity (FVC) of 98.4 mL, contrasting sharply with a mean decline of -62.3 mL in the placebo group. ?? Quality of Life Boost: The highest dose group also experienced a significant 2-point improvement on the Leicester Cough Questionnaire (LCQ), indicating better symptom control and quality of life. ?? Safety: ISM001-055 was well-tolerated, with only mild side effects reported, primarily gastrointestinal issues and minor liver function changes. ?? What’s Next? To build on these results, Insilico is now recruiting for a parallel Phase IIa trial in the United States to further validate the efficacy and safety of ISM001-055. If successful, this drug could shift the treatment paradigm for IPF. ?? Broader Impact Insilico Medicine’s PharmaAI platform seems to be a productive tool for designing first-in-class treatments faster (and arguably, quite efficiently, judring by ongoing clinical progress). Since 2021, Pharma.AI helped nominate over 20 preclinical candidates across a portfolio of more than 30 assets, with 9 molecules receiving IND approvals. ISM001-055, discovered and designed using @PharmaAI’s Biology42 (PandaOmics) and Chemistry42 modules, is the latest example of how AI can make impact on complex, life-threatening diseases like IPF. An important test for company's abilities will probably be next year when a landmark Phase III trima may launch. Full coverage on BioPharmaTrend.com (link in the comments). Image credit: Insilico Medicine

We’re excited to share the latest updates to enhance your Science42: #DORA experience: ?? Trial Document Generation -Trial users can now generate up to 3 free documents to explore DORA’s capabilities before committing to a subscription. ?? Enhanced Editing -Automatically remove deleted citations from the Bibliography list and exported files. -Bibliography Cleanup ensures your references stay accurate and organized. ?? Transparency logs Improvements -Transparency now reflects the correct generation order for better clarity. -New statuses: "In Progress" and "Complete" for document generation tracking. -Additional agent actions provide deeper insights into the content creation process. ?? Performance Boost -Optimized web search and file upload performance with improved embedding token handling. -Token consumption is now included in the weekly statistics report for easier usage monitoring. Get started today ?? https://pharma.ai/dora #AIGeneration #DocumentGenerator #Publications

Dr. Petrina Kamya, Ph.D. joins the AI Summit Keynote speaker lineup, hosted by Boehringer Ingelheim, on Friday, November 22 in Ridgefield, CT! This first-ever event will converge AI thought leadership, showcase #innovation, and propel the State of Connecticut forward as a leader in #AI. Learn more about this new event here: https://lnkd.in/eEmzpfhk #AISummit #InsilicoMedicine #AISummitConnecticut

?? Beginning later this morning at 11:30 am EST! Pharma.AI Week kicks off with the PandaOmics and Science42: #DORA session. You will hear an overview of all new features now available on both platforms. Science42: DORA -Agentic Research -Web Search -Generation Transparency PandaOmics -Self Service Registration -Gene-disease association evidence from gene mutation data We hope to see you there! ?? https://lnkd.in/eH9pkfRV

? ? Have you registered for Pharma.AI Week yet? Beginning TOMORROW, the 3-day event will provide an exclusive look into the latest advancements and innovations within the?Pharma.AI?platform, which comprises Biology42, Chemistry42, Medicine42 and Science42. ?? We hope you and your colleagues will join us: https://lnkd.in/eH9pkfRV #Chemistry42 #PandaOmics #InsilicoWebinars #PharmaAI #PharmaAIWeek #DORA #TechWebinars #AI

?? Hot off the press from Fierce Biotech Insilico's AI-designed med tied to #respiratoryhealth improvements in midstage lung disease trial Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated improvements in a respiratory health measure for patients with idiopathic pulmonary fibrosis (#IPF). Read the full article here: https://lnkd.in/eds_UNXc #FierceBiotech #PhaseIIa #RespiratoryHealth